Moreover, upregulation of SOX4 has been associated with breast cancer and proposed to be the master regulator of epithelial-to-mesenchymal transition34, which again suggests mutants in ZnT2 may impair the secretory phenotype, and may affect risk for breast disease. The gene discussed is SOX4; the disease is breast carcinoma.